The FDA approved Portola's anti-Xa direct oral anticoagulant Betrixaban as Bevyxxa on June 23, 2017. Click or tap here for the FDA announcement and here for Portola's press release, indications, and prescribing information. Thanks to Dr. Ali Sadeghi-Khomami of Precision BioLogic for sending along the announcement.
Posts - Anticoagulant Therapy
Jun 27, 2017 8:13am
Jun 10, 2017 7:47am
May 30, 2017 3:07am
Click here for an excellent MedScape review on the DOACs.
May 23, 2017 3:40am
From Maureen Tacke, Idaho; Hi George, my colleagues and I enjoy the Fratsma Factor postings you send. Thank you for the work that you do instilling best practice across the nation. Each year at the PTT lot change, we redo the heparin response curve. We’ve done this to follow practices from years prior. We’ve noted in the CAP checklist that after the initial response curve, it is only necessary to compare the current lot with the new lot of PTT. We are considering changing practices, and wanted to hear your thoughts on the matter. CAP does not dictate the correlation coefficient range between lots. What would you recommend? 0.9 – 1.1? Smaller? Eventually, we’d like to change practice within our pharmacy so that they monitor patients via anti-Xa. But we are not quite to that point yet with our pharmaceutical colleagues. Thank you for your time.